cisapride has been researched along with terfenadine in 40 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (2.50) | 18.2507 |
| 2000's | 26 (65.00) | 29.6817 |
| 2010's | 13 (32.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Brown, AM; Dennis, A; Rampe, D; Roy, ML | 1 |
| Cavalli, A; De Ponti, F; Poluzzi, E; Recanatini, M | 1 |
| Chen, XL; Hendrix, J; Kang, J; Korolev, AM; Lysenkova, LN; Miroshnikova, OV; Pearlstein, RA; Preobrazhenskaya, M; Rampe, D; Shchekotikhin, AE; Vaz, RJ | 1 |
| Pearlstein, R; Rampe, D; Vaz, R | 1 |
| Keserü, GM | 1 |
| Li, J; Rajamani, R; Reynolds, CH; Tounge, BA | 1 |
| Nagashima, R; Nishikawa, T; Tobita, M | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Bleich, S; Gulbins, E; Kornhuber, J; Reichel, M; Terfloth, L; Tripal, P; Wiltfang, J | 1 |
| Jia, L; Sun, H | 1 |
| Caron, G; Ermondi, G; Visentin, S | 1 |
| Imai, YN; Oiki, S; Ryu, S | 1 |
| Giordanetto, F; Leach, AG; Zachariae, U | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Abu Khalaf, R; Abu Sheikha, G; Bustanji, Y; Taha, MO | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Sen, S; Sinha, N | 1 |
| Cooper, J; Cui, Y; Fink, M; Gavaghan, DJ; Heath, BM; McMahon, NC; Mirams, GR; Noble, D; Sher, A | 1 |
| Freiwald, S; Jiang, Y; Jones, JP; Kaspera, R; Katayama, J; Lee, CA; Smith, E; Totah, RA; Walker, GS | 1 |
| Fijorek, K; Glinka, A; Mendyk, A; Polak, S; Wiśniowska, B | 1 |
| Brown, AM; Bruening-Wright, A; Kramer, J; Kuryshev, YA; Myatt, G; Obejero-Paz, CA; Verducci, JS | 1 |
| Gunston, GD; Mehta, U | 1 |
| Paakkari, I | 1 |
| Avery, MJ; DePasquale, MJ; Fossa, AA; Leishman, DJ; Raunig, DL | 1 |
| Sugiyama, A | 1 |
| Fernandez, D; Ghanta, A; Kauffman, GW; Sanguinetti, MC | 1 |
| Avery, M; Fermini, B; Fossa, AA; Raunig, DL; Wang, E; Wisialowski, T; Wolfgang, E | 1 |
| Furuta, S; Kamada, E; Kawabata, Y; Kurimoto, T; Omata, T; Sugimoto, T; Wu, XC; Yonezawa, K | 1 |
| Abe, J; Hamada, Y; Harada, T; Hashimoto, K; Horii, I; Sawada, Y; Shiotani, M | 1 |
| Cox, BF; Fischer, C; Gintant, GA; Limberis, JT; Long, MA; Martin, RL; Mikhail, A; Patel, A; Su, Z | 1 |
| Darpö, B | 1 |
| Vos, MA | 1 |
| Dabhi, J; Mehta, A | 1 |
| Honjo, H; Kamiya, K; Morishima, M; Niwa, R; Sanguinetti, MC | 1 |
| Dirks, P; Feigenspan, A; Trümpler, J; Weiler, R | 1 |
| Aqvist, J; Boukharta, L; de Groot, BL; Karimi-Nejad, Y; Stary, A; Vriend, G; Wacker, SJ; Zachariae, U | 1 |
| Fujii, M; Imaizumi, Y; Ohya, S; Yamamura, H | 1 |
| Clancy, CE; Romero, L; Saiz, J; Trenor, B; Yang, PC | 1 |
| Claydon, T; Grajauskas, L; Lo, G; Thouta, S | 1 |
5 review(s) available for cisapride and terfenadine
| Article | Year |
|---|---|
Understanding the structure-activity relationship of the human ether-a-go-go-related gene cardiac K+ channel. A model for bad behavior.
Topics: Cation Transport Proteins; DNA-Binding Proteins; Drug-Related Side Effects and Adverse Reactions; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Long QT Syndrome; Models, Molecular; Pharmaceutical Preparations; Potassium Channels; Potassium Channels, Voltage-Gated; Structure-Activity Relationship; Torsades de Pointes; Trans-Activators; Transcriptional Regulator ERG | 2003 |
Cardiotoxicity of new antihistamines and cisapride.
Topics: Arrhythmias, Cardiac; Astemizole; Benzimidazoles; Butyrophenones; Cetirizine; Cisapride; Heart Diseases; Histamine H1 Antagonists; Humans; Loratadine; Piperidines; Serotonin Receptor Agonists; Terfenadine; Triprolidine | 2002 |
[Effects of clinically available drugs on the repolarization process of the heart assessed by the in vivo canine models].
Topics: Action Potentials; Animals; Anti-Arrhythmia Agents; Antipsychotic Agents; Antitubercular Agents; Cation Transport Proteins; Cisapride; Disease Models, Animal; Dogs; Ether-A-Go-Go Potassium Channels; Fluoroquinolones; Gastrointestinal Agents; Haloperidol; Histamine H1 Antagonists; Long QT Syndrome; Potassium Channels; Potassium Channels, Voltage-Gated; Sulpiride; Terfenadine; Torsades de Pointes | 2003 |
Detection and reporting of drug-induced proarrhythmias: room for improvement.
Topics: Adverse Drug Reaction Reporting Systems; Arrhythmias, Cardiac; Cisapride; Drug Labeling; Gastrointestinal Agents; Histamine H1 Antagonists, Non-Sedating; Humans; Pharmacoepidemiology; Terfenadine | 2007 |
Literature-based evaluation of four 'hard endpoint' models for assessing drug-induced torsades de pointes liability.
Topics: Animals; Aza Compounds; Cisapride; Dogs; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Electrocardiography; Fluoroquinolones; Humans; Models, Biological; Moxifloxacin; Quinolines; Rabbits; Risk Assessment; Terfenadine; Torsades de Pointes | 2008 |
35 other study(ies) available for cisapride and terfenadine
| Article | Year |
|---|---|
A mechanism for the proarrhythmic effects of cisapride (Propulsid): high affinity blockade of the human cardiac potassium channel HERG.
Topics: Arrhythmias, Cardiac; Cation Transport Proteins; Cell Line; Cisapride; DNA-Binding Proteins; Electrophysiology; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Heart; Humans; Kv1.5 Potassium Channel; Myocardium; Patch-Clamp Techniques; Phenethylamines; Piperidines; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Sulfonamides; Terfenadine; Trans-Activators; Transcriptional Regulator ERG; Transfection; Tumor Cells, Cultured | 1997 |
Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers.
Topics: Anti-Arrhythmia Agents; Cation Transport Proteins; Cluster Analysis; Databases, Factual; Ether-A-Go-Go Potassium Channels; Long QT Syndrome; Models, Molecular; Molecular Conformation; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship | 2002 |
Characterization of HERG potassium channel inhibition using CoMSiA 3D QSAR and homology modeling approaches.
Topics: Amino Acids, Aromatic; Cation Transport Proteins; DNA-Binding Proteins; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Hydrophobic and Hydrophilic Interactions; Imidazoles; Indoles; Inhibitory Concentration 50; Models, Molecular; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Protein Binding; Protein Conformation; Quantitative Structure-Activity Relationship; Structural Homology, Protein; Structure-Activity Relationship; Trans-Activators; Transcriptional Regulator ERG | 2003 |
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
Topics: Cation Transport Proteins; Databases, Factual; Discriminant Analysis; Ether-A-Go-Go Potassium Channels; Holography; Linear Models; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship | 2003 |
A two-state homology model of the hERG K+ channel: application to ligand binding.
Topics: ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Ligands; Models, Biological; Models, Molecular; Potassium Channels, Voltage-Gated; Protein Binding; Protein Conformation | 2005 |
A discriminant model constructed by the support vector machine method for HERG potassium channel inhibitors.
Topics: Animals; CHO Cells; Cricetinae; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Potassium Channel Blockers; Potassium Channels, Voltage-Gated | 2005 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
Topics: Algorithms; Animals; Cell Line; Cell Line, Tumor; Chemical Phenomena; Chemistry, Physical; Enzyme Inhibitors; Humans; Hydrogen-Ion Concentration; Molecular Conformation; Quantitative Structure-Activity Relationship; Rats; Sphingomyelin Phosphodiesterase | 2008 |
Support vector machines classification of hERG liabilities based on atom types.
Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Chemical; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Predictive Value of Tests; ROC Curve | 2008 |
GRIND-based 3D-QSAR and CoMFA to investigate topics dominated by hydrophobic interactions: the case of hERG K+ channel blockers.
Topics: Ether-A-Go-Go Potassium Channels; Humans; Hydrophobic and Hydrophilic Interactions; Models, Molecular; Potassium Channel Blockers; Quantitative Structure-Activity Relationship | 2009 |
Docking model of drug binding to the human ether-à-go-go potassium channel guided by tandem dimer mutant patch-clamp data: a synergic approach.
Topics: Amino Acid Sequence; Binding Sites; Cell Line; Cisapride; Dimerization; Ether-A-Go-Go Potassium Channels; Humans; Models, Molecular; Molecular Sequence Data; Mutation; Patch-Clamp Techniques; Piperidines; Pyridines; Sequence Homology, Amino Acid; Terfenadine | 2009 |
Side chain flexibilities in the human ether-a-go-go related gene potassium channel (hERG) together with matched-pair binding studies suggest a new binding mode for channel blockers.
Topics: Binding Sites; Ether-A-Go-Go Potassium Channels; Humans; Hydrophobic and Hydrophilic Interactions; Ligands; Models, Molecular; Potassium Channel Blockers; Protein Binding; Protein Conformation | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Discovery of new cholesteryl ester transfer protein inhibitors via ligand-based pharmacophore modeling and QSAR analysis followed by synthetic exploration.
Topics: Cholesterol Ester Transfer Proteins; Drug Discovery; Hydrogen Bonding; Ligands; Models, Molecular; Molecular Structure; Quantitative Structure-Activity Relationship; ROC Curve | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship | 2011 |
Simulation of multiple ion channel block provides improved early prediction of compounds' clinical torsadogenic risk.
Topics: Action Potentials; Animals; Calcium Channel Blockers; Calcium Channels, L-Type; Computer Simulation; Dogs; Dose-Response Relationship, Drug; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Guinea Pigs; HEK293 Cells; Humans; Ion Channels; Kinetics; Models, Cardiovascular; NAV1.5 Voltage-Gated Sodium Channel; Patch-Clamp Techniques; Potassium Channel Blockers; Rabbits; Risk Assessment; Risk Factors; Sodium Channel Blockers; Sodium Channels; Torsades de Pointes; Transfection | 2011 |
Identifying a selective substrate and inhibitor pair for the evaluation of CYP2J2 activity.
Topics: Amiodarone; Astemizole; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2J2; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Danazol; Drug Discovery; Drug Interactions; Enzyme Inhibitors; Humans; Hydroxylation; In Vitro Techniques; Methylation; Microsomes, Liver; Models, Biological; Molecular Structure; Substrate Specificity; Tandem Mass Spectrometry; Terfenadine | 2012 |
Predictive model for L-type channel inhibition: multichannel block in QT prolongation risk assessment.
Topics: Artificial Intelligence; Calcium Channel Blockers; Calcium Channels, L-Type; Cell Line; Computational Biology; Computer Simulation; Drugs, Investigational; Ether-A-Go-Go Potassium Channels; Expert Systems; Heart Rate; Humans; Models, Biological; Myocytes, Cardiac; NAV1.5 Voltage-Gated Sodium Channel; Potassium Channel Blockers; Quantitative Structure-Activity Relationship; Risk Assessment; Shaker Superfamily of Potassium Channels; Torsades de Pointes; Voltage-Gated Sodium Channel Blockers | 2012 |
MICE models: superior to the HERG model in predicting Torsade de Pointes.
Topics: ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Theoretical; Patch-Clamp Techniques; Predictive Value of Tests; Torsades de Pointes | 2013 |
Potentially serious drug interactions with grapefruit juice.
Topics: Benzodiazepines; Beverages; Calcium Channel Blockers; Cisapride; Citrus; Cyclosporine; Cytochrome P-450 Enzyme Inhibitors; Drug Prescriptions; Food-Drug Interactions; Herb-Drug Interactions; Humans; Terfenadine | 2000 |
The relationship of clinical QT prolongation to outcome in the conscious dog using a beat-to-beat QT-RR interval assessment.
Topics: Animals; Anti-Arrhythmia Agents; Butylamines; Cisapride; Disease Models, Animal; Dogs; Female; Heart Rate; Long QT Syndrome; Male; Piperidines; Pyridines; Terfenadine; Verapamil | 2002 |
Physicochemical features of the HERG channel drug binding site.
Topics: Amino Acid Motifs; Amino Acid Sequence; Animals; Benzopyrans; Binding Sites; Biophysical Phenomena; Biophysics; Cation Transport Proteins; Cisapride; Ether-A-Go-Go Potassium Channels; Histamine H1 Antagonists; Inhibitory Concentration 50; Kinetics; Models, Molecular; Molecular Sequence Data; Mutation; Oocytes; Phenylalanine; Piperidines; Point Mutation; Potassium Channels; Potassium Channels, Voltage-Gated; Protein Binding; Protein Structure, Tertiary; RNA, Complementary; Sequence Homology, Amino Acid; Serotonin Receptor Agonists; Temperature; Terfenadine; Tyrosine; Xenopus | 2004 |
Differential effect of HERG blocking agents on cardiac electrical alternans in the guinea pig.
Topics: Animals; Antipsychotic Agents; Bepridil; Blood Pressure; Calcium Channel Blockers; Calcium Channels, L-Type; Cisapride; Delayed Rectifier Potassium Channels; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Gastrointestinal Agents; Guinea Pigs; Heart Rate; Histamine H1 Antagonists; Humans; In Vitro Techniques; Male; Myocytes, Cardiac; Patch-Clamp Techniques; Piperidines; Potassium Channels, Voltage-Gated; Pyridines; Risperidone; Terfenadine; Verapamil | 2004 |
Drug-drug interactions of Z-338, a novel gastroprokinetic agent, with terfenadine, comparison with cisapride, and involvement of UGT1A9 and 1A8 in the human metabolism of Z-338.
Topics: Benzamides; Cell Line; Cisapride; Dose-Response Relationship, Drug; Drug Interactions; Gastrointestinal Agents; Glucuronosyltransferase; Humans; Male; Microsomes, Liver; Terfenadine; Thiazoles; UDP-Glucuronosyltransferase 1A9 | 2004 |
Practical application of guinea pig telemetry system for QT evaluation.
Topics: Animals; Anti-Arrhythmia Agents; Antipsychotic Agents; Bepridil; Cisapride; Disease Models, Animal; Electrocardiography; Guinea Pigs; Haloperidol; Heart; Humans; Injections, Intravenous; Long QT Syndrome; Male; Nifedipine; Pimozide; Piperidines; Pyridines; Quinidine; Reproducibility of Results; Telemetry; Terfenadine; Thioridazine | 2005 |
Hydroxypropyl beta-cyclodextrins: a misleading vehicle for the in vitro hERG current assay.
Topics: 2-Hydroxypropyl-beta-cyclodextrin; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; beta-Cyclodextrins; Biological Assay; Cisapride; Dose-Response Relationship, Drug; Electrophysiology; Ether-A-Go-Go Potassium Channels; Excipients; Gastrointestinal Agents; Histamine H1 Antagonists; Humans; Inhibitory Concentration 50; Myocytes, Cardiac; Piperidines; Potassium Channel Blockers; Pyridines; Solubility; Terfenadine; Time Factors | 2007 |
QT prolongation and safety in the Indian population.
Topics: Astemizole; Cisapride; Databases, Factual; Drug-Related Side Effects and Adverse Reactions; Electrocardiography; Histamine H1 Antagonists, Non-Sedating; Humans; India; Long QT Syndrome; Serotonin Receptor Agonists; Terfenadine; Torsades de Pointes | 2007 |
Molecular determinants of hERG channel block by terfenadine and cisapride.
Topics: Animals; Binding Sites; Cisapride; Dose-Response Relationship, Drug; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Gastrointestinal Agents; Gene Transfer Techniques; Histamine H1 Antagonists, Non-Sedating; Humans; Membrane Potentials; Mutagenesis; Potassium Channel Blockers; Protein Conformation; Terfenadine; Time Factors; Xenopus laevis | 2008 |
Ether-à-gogo-related gene (erg1) potassium channels shape the dark response of horizontal cells in the mammalian retina.
Topics: Animals; Axons; Cisapride; Darkness; Electrophysiological Phenomena; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Glutamic Acid; Haloperidol; Immunohistochemistry; Mice; Mice, Inbred C57BL; Patch-Clamp Techniques; Retinal Horizontal Cells; Synapses; Terfenadine; Tetraethylammonium | 2009 |
Toward a consensus model of the HERG potassium channel.
Topics: Amino Acid Sequence; Benzopyrans; Cisapride; Crystallography, X-Ray; Ether-A-Go-Go Potassium Channels; Humans; Molecular Dynamics Simulation; Molecular Sequence Data; Piperidines; Protein Binding; Protein Conformation; Protein Structure, Tertiary; Sequence Alignment; Terfenadine | 2010 |
Development of recombinant cell line co-expressing mutated Nav1.5, Kir2.1, and hERG for the safety assay of drug candidates.
Topics: Action Potentials; Biological Assay; Cell Line; Cisapride; Drug Evaluation, Preclinical; Ether-A-Go-Go Potassium Channels; HEK293 Cells; High-Throughput Screening Assays; Humans; NAV1.5 Voltage-Gated Sodium Channel; Patch-Clamp Techniques; Piperidines; Potassium Channel Blockers; Potassium Channels, Inwardly Rectifying; Pyridines; Pyrimidinones; Sodium Channels; Terfenadine; Transfection; Verapamil | 2012 |
In silico screening of the impact of hERG channel kinetic abnormalities on channel block and susceptibility to acquired long QT syndrome.
Topics: Action Potentials; Anti-Arrhythmia Agents; Astemizole; Cisapride; Computer Simulation; Gene Expression; Genetic Predisposition to Disease; Heart Ventricles; Humans; Ion Channel Gating; Kinetics; Long QT Syndrome; Models, Statistical; Mutation; Phenethylamines; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Protein Conformation; Severity of Illness Index; Sotalol; Sulfonamides; Terfenadine | 2014 |
Investigating the state dependence of drug binding in hERG channels using a trapped-open channel phenotype.
Topics: Action Potentials; Animals; Cisapride; ERG1 Potassium Channel; Microelectrodes; Mutation; Oocytes; Patch-Clamp Techniques; Protein Structure, Tertiary; Recombinant Proteins; Structure-Activity Relationship; Terfenadine; Xenopus laevis | 2018 |